Abstract:Postherpetic neuralgia (PHN) is a painful and refractory complication of herpes zoster. Treatments are either partially or totally ineffective for many people with PHN. Antiviral agents, used at the time of the rash, have been proposed as an intervention to prevent the development of PHN. This is the first update since the first publication of the review in 2009.To assess the effectiveness of antiviral agents in preventing PHN.On 26 April 2013, we updated the searches in the Cochrane Neuromuscular Disease Group Specialized Register, CENTRAL, MEDLINE, EMBASE, LILACS, and the Chinese Biomedical Retrieval System. We checked the references of published studies to identify additional trials, and contacted authors to obtain additional data. We searched other databases in The Cochrane Library for information for the Discussion and two clinical trials registries for ongoing trials.We considered all randomised controlled trials (RCTs) of antiviral treatment given within 72 hours after the onset of herpes zoster for preventing PHN. There were no language restrictions.Two authors independently selected trials, evaluated the risk of bias in included trials, and extracted and analysed data.Six RCTs with a total of 1211 participants were eligible; five trials evaluated oral aciclovir, and one, with 419 participants, evaluated oral famciclovir. We were able to conduct meta-analyses as there were sufficient similarities in the included studies, such as the reporting of the presence of PHN, duration of rash before treatment initiation and treatment regimen. For our primary outcome, based on three trials (609 participants) we found no significant difference between the aciclovir and control groups in the incidence of PHN four months after the onset of the acute herpetic rash (risk ratio (RR) 0.75, 95% confidence interval (CI) 0.51 to 1.11), nor was there a significant difference at six months (RR 1.05, 95% CI 0.87 to 1.27, two trials, 476 participants). In four of the trials (692 participants), there was some evidence for a reduction in the incidence of pain four weeks after the onset of rash. In the trial of famciclovir versus placebo, neither 500 mg nor 750 mg doses of famciclovir reduced the incidence of herpetic neuralgia significantly. The most commonly reported adverse events were nausea, vomiting, diarrhoea and headache for aciclovir, and headache and nausea for famciclovir. For neither treatment was the incidence of adverse events significantly different from placebo. None of the studies were at high risk of bias, although the risk of bias was unclear in at least one domain for all but one study. We found no new RCTs when we updated the searches in April 2013.There is high quality evidence that oral aciclovir does not reduce the incidence of PHN significantly. In addition, there is insufficient evidence to determine the effect of other antiviral treatments; therefore, further well-designed RCTs are needed to investigate famciclovir or other new antiviral agents in preventing PHN. Future trials should pay more attention to the severity of pain and quality of life of participants, and should be conducted among different subgroups of people, such as people who are immunocompromised.

Effectiveness of pregabalin as a secondary treatment for neuropathic pain from postherpetic neuralgia

A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Pregabalin for Postherpetic Neuralgia in A Population of Chinese Patients

Efficacy of Pregabalin in the Treatment of Postherpetic Neuralgia : a Meta-Analysis of Randomized Controlled Trials

Comparing the Efficacy and Safety of High-Voltage and Standard-Voltage Pulsed Radiofrequency for the Treatment of Postherpetic Neuralgia: a Pooled Analysis from Randomized Controlled Trials

The efficacy of pregabalin for acute pain control in herpetic neuralgia patients: A meta-analysis.

Efficacy and Safety of Gabapentinoids for Acute Herpes Zoster Neuralgia

Efficacy and Safety of Gabapentinoids for Acute Herpes Zoster Neuralgia: A Systematic Review and Meta-analysis of Randomized Controlled Trials

Effects of pregabalin on acute herpetic pain and postherpetic neuralgia incidence

The Effectiveness and Safety of Domestic Gabapentin in the Management of Post-Herpetic Neuralgia

A Meta-Analysis of Therapeutic Efficacy and Safety of Gabapentin in the Treatment of Postherpetic Neuralgia from Randomized Controlled Trials

Intravenous Patient-Controlled Analgesia Hydromorphone Combined with Pregabalin for the Treatment of Postherpetic Neuralgia: a Multicenter, Randomized Controlled Study

The Cost-Effectiveness of Pregabalin Versus Gabapentin for Peripheral Neuropathic Pain (pNeP) and Postherpetic Neuralgia (PHN) in China

A Meta-analysis of Randomized Controlled Trials Comparing the Efficacy and Safety of Pregabalin and Gabapentin in the Treatment of Postherpetic Neuralgia

The Effectiveness of Repetitive Paravertebral Injections with Local Anesthetics and Steroids for the Prevention of Postherpetic Neuralgia in Patients with Acute Herpes Zoster

THE EFFICACY AND SAFETY OF GABAPENTIN IN POSTHERPETIC NEURALGIA

Effective Pain Management of Postherpetic Neuralgia Using a Combination of Analgesics and Conservative Measures

Meta-analysis of Gabapentin in the Treatment of Postherpetic Neuralgia

Antiviral Treatment for Preventing Postherpetic Neuralgia.

Post-herpetic neuralgia in older adults: evidence-based approaches to clinical management

Treatment of Postherpetic Neuralgia With Intravenous Administration of Zinc Sulfate: A Case Report

Efficacy and safety of pulsed radiofrequency combined with pregabalin for herpetic neuralgia: A systematic review and meta-analysis